A phase I/II study of JX-594 oncolytic virus in combination with immune checkpoint inhibition in refractory colorectal cancer. (October 2020) - Monge, C.; Xie, C.; Brar, G.; Akoth, E.; Webb, S.; Mabry, D.; Redd, B.; Levy, E.; Wood, B.; Greten, T.